Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Gains from Investment Securities (2023 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Gains from Investment Securities for 4 consecutive years, with $125000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 87.11% to $125000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $125000.0, a 96.65% decrease, with the full-year FY2023 number at $9.7 million, up 4814.08% from a year prior.
  • Gains from Investment Securities was $125000.0 for Q3 2025 at Centessa Pharmaceuticals, up from -$3.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $9.7 million in Q1 2023 to a low of -$3.7 million in Q4 2024.
  • A 4-year average of $1.6 million and a median of $547500.0 in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 87.11% in 2025; the steepest drop was 87.11% in 2025.
  • Centessa Pharmaceuticals' Gains from Investment Securities stood at -$206000.0 in 2022, then skyrocketed by 4814.08% to $9.7 million in 2023, then plummeted by 138.42% to -$3.7 million in 2024, then surged by 103.35% to $125000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Gains from Investment Securities are $125000.0 (Q3 2025), -$3.7 million (Q4 2024), and $970000.0 (Q3 2024).